TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Mayne Pharma Group ( (AU:MYX) ).
Mayne Pharma Group Limited has requested a trading halt on its securities pending the release of a material announcement regarding a proposed acquisition by Cosette through a scheme of arrangement. This move is expected to have significant implications for the company’s operations and market positioning, as it could potentially lead to strategic realignment and impact stakeholders involved.
The most recent analyst rating on (AU:MYX) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is a pharmaceutical company listed on the Australian Securities Exchange (ASX: MYX). The company is involved in the development and manufacturing of branded and generic pharmaceutical products, with a focus on delivering innovative solutions in the healthcare sector.
Average Trading Volume: 446,792
Technical Sentiment Signal: Sell
Current Market Cap: A$381.9M
See more insights into MYX stock on TipRanks’ Stock Analysis page.